• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

The Microbiome and Nonalcoholic Fatty Liver Disease

W

Wally

Senior Member
Messages
1,167
Receptor may be key to treating nonalcoholic fatty liver disease

[A]ccording to this study and earlier research, tempol [an antioxidant drug] and antibiotics appear to reduce some types of Lactobacillus -- an intestinal bacteria that converts lactose and other sugars into lactic acid. When Lactobacillus levels decrease, a bile acid -- tauro-beta-muricholic acid -- increases. The increase of this bile acid then directly inhibits FXR -- farnesoid X receptor, which regulates the metabolism of bile acids, fats and glucose in the body. . . .

"What our team found is that, if we genetically disrupt FXR expression in the intestinal epithelium, or inhibit it with tempol or antibiotics, we can prevent the development of NAFLD and obesity," . . . .

This study is another indication of the complex role that gut microbes play in human health, as well as how they may serve as possible targets for treating metabolic disorders . . . .
Click to expand...

Click here to read to more about this study - http://www.sciencedaily.com/releases/2014/12/141215185157.htm
 
You must log in or register to reply here.